CDC Data Shows Youth Cannabis Use Declines in Legalization States
New federal surveillance data undermines the gateway-drug argument that has anchored prohibition for decades.

Group of diverse teenagers hanging out in a school hallway, chatting and enjoying each other's company.
Survey Tracks 15-Year Trend Across Legal and Prohibition Jurisdictions
The CDC analyzed Youth Risk Behavior Survey responses from 2011 through 2025, covering more than 400,000 high school students in states with and without legal cannabis markets. Past-30-day use among students in legalization states fell from 23.1 percent in 2011 to 19.4 percent in 2025. Prohibition states saw a smaller decline over the same window—from 22.7 percent to 21.2 percent—according to the report published in the CDC's Morbidity and Mortality Weekly Report.
The survey defined past-30-day use as any self-reported cannabis consumption in the month prior to the questionnaire. Researchers controlled for demographic variables including age, gender, race, and socioeconomic status.
States included in the legalization cohort had operational retail markets for at least 24 months at the time of survey administration. Medical-only states didn't make the cut.
Retail Regulation Tightens Youth Access Points
Regulated dispensaries require government-issued ID and maintain transaction logs subject to state audit, creating enforcement barriers absent in illicit markets. Fourteen of 24 legalization states imposed additional penalties for selling to minors beyond those in place under prohibition. Fines range from $10,000 to $50,000 per violation, with potential license revocation on the table.
Compliance checks conducted by state cannabis control agencies in California, Colorado, and Washington between 2022 and 2025 found that licensed retailers refused sales to underage decoys in 92 percent of attempts. By comparison, a 2019 National Institute on Drug Abuse study found that illicit dealers sold to minors in 74 percent of controlled-buy scenarios.
Gateway Theory Loses Empirical Support
The data directly challenges the Controlled Substances Act's Schedule I classification rationale, which cites high abuse potential and lack of accepted safety for use even under medical supervision. Federal agencies including the Drug Enforcement Administration have historically argued that cannabis serves as a gateway drug, increasing the likelihood of adolescent progression to harder substances. The numbers tell a different story.
The CDC report found no statistically significant increase in opioid, cocaine, or methamphetamine use among high school students in legalization states during the survey period. Past-30-day opioid misuse declined from 5.3 percent in 2011 to 3.1 percent in 2025 across all surveyed states, with no meaningful variance between legal and prohibition jurisdictions.
For additional context on federal scheduling and the DEA's ongoing review, see the CannIntel topic hub on youth cannabis use and legalization.
State-Level Variance Points to Policy Design
Youth-use declines were most pronounced in states that allocated cannabis tax revenue to prevention and education programs. Colorado, which directs 12.6 percent of excise tax collections to school-based substance-use prevention, saw a 14 percent drop in high school past-30-day use between 2014 and 2025. Oregon, which allocates 3.8 percent to similar programs, recorded a 6 percent decline over the same period.
States without dedicated prevention funding—including Nevada and Michigan—showed smaller but still measurable declines of 4 to 5 percent. Causation? The CDC report didn't establish it, but noted the correlation as worthy of further study.
Implications for Federal Rescheduling Debate
The findings arrive as the DEA weighs a proposed rule to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, 21 U.S.C. § 812. The agency's Notice of Proposed Rulemaking, published in May 2024, cited evolving scientific evidence on medical efficacy and abuse potential but didn't address youth-use trends in legalization states.
Public comments on the NPRM closed in July 2024, with more than 43,000 submissions. The DEA hasn't announced a timeline for a final rule. Rescheduling to Schedule III wouldn't legalize cannabis federally but would remove certain research barriers and allow state-legal businesses to deduct ordinary expenses under 26 U.S.C. § 280E.
What Comes Next
The CDC plans to release updated Youth Risk Behavior Survey data annually. Researchers noted that the 2026 survey will be the first to capture post-pandemic behavioral trends with a full return to in-person schooling. That's a clean baseline.
State legislatures in Pennsylvania, Ohio, and Kentucky—all considering adult-use legalization bills in 2027—have cited youth-use data as a key variable in their deliberations. Pennsylvania House Bill 2170, introduced in August 2026, includes a provision requiring annual youth-consumption reports as a condition of the program's continuation.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

Idaho Ballot Measure Blocks Corporate-Funded Cannabis Legalization Campaigns
Proposed constitutional amendment would bar out-of-state entities from financing future marijuana legalization efforts in Idaho.

Chesapeake Advances Zoning Rules for Adult-Use Cannabis Retail
City council takes initial step toward regulating where recreational marijuana dispensaries can operate in Virginia's second-largest city.

Cannabis Insurance Bill Seeks to Expand US Insurer Participation
Federal legislation aims to remove regulatory barriers preventing traditional insurers from serving state-legal cannabis operators.
More from the newsroom

Aurora Files Complaint with Alberta Regulator Over Curaleaf Bid Deficiencies
Canadian MSO alleges material disclosure gaps in Curaleaf's hostile takeover offer, escalating cross-border M&A fight.

Mainstream Insurers Push Federal Bill to Enter Cannabis Market
CLAIM Act targets federal-state conflict blocking carriers post-rescheduling, mirroring SAFE Banking playbook for insurance sector.

Connecticut Cannabis Sales Jump 27% But Revenue Gains Lag Amid Price Collapse
Retailers sold 27.5% more product in first eight months of 2026, yet revenue rose just 6.8% as unit prices fell.